Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Eli Lilly & Company patentsThe following is a sampling of recent Eli Lilly & Company patent applications (USPTO Patent Application #, Patent Title) sorted by month.
April 2008 - Eli Lilly & Company patents
20080096811 - Selective vpac2 receptor peptide agonists
20080096871 - Olanzapine pamoate dihydrate
20080096923 - Methods for diagnosing and treating diabetic microvascular complications
20080096930 - Potentiators of glutamate receptors
20080089892 - Fc region variants
20080085860 - Selective vpac2 receptor peptide agonists
March 2008 - Eli Lilly & Company patents
20080064742 - Substituted benzopyrans as selective estrogen receptor-beta agonists
20080058385 - A crystalline variable hydrate of (s)-6-(4-(2-((3-9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
February 2008 - Eli Lilly & Company patents
20080050375 - Binding compositions: related reagents
20080051359 - Antisense oligonucleotide modulation of stat3 expression
20080032932 - Method of reducing mortality and morbidity associated with critical illnesses
20080032948 - Novel antifolate combination therapies
January 2008 - Eli Lilly & Company patents
20080026996 - Selective vpac2 receptor reptide agonists
20080027102 - Quinolinyl-pyrrolopyrazoles
20080027397 - Medication dispensing apparatus with triple screw threads for mechanical advantage
20080020387 - Biomarker-optimized adhd treatment
20080015235 - Histamine h3 receptor inhibitors, preparation and therapeutic uses
20080015358 - Fluorination process of protected aminothiazole
20080009433 - Use of glp-1 or analogs in treatment of myocardial infarction
20080004321 - Potentiators of glutamate receptors
20080004330 - Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake
December 2007 - Eli Lilly & Company patents
20070299007 - Muteins of fibroblast growth factor 21
20070299053 - Lactam compound
20070293423 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide
20070293430 - Muteins of fibroblast growth factor 21
20070287751 - Opioid receptor antagonists
20070281946 - Tri(cyclo) substituted amide compounds
20070281988 - Combination therapy for vascular complications associated with hyperglycemia
November 2007 - Eli Lilly & Company patents
20070270465 - Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl) piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
20070265200 - Glycol linked fgf-21 compounds
20070265342 - Prodrugs of excitatory amino acids
20070253966 - Fusion proteins
20070254869 - Compounds and methods for treating dislipidemia
October 2007 - Eli Lilly & Company patents
20070249623 - 1-(indole-6-carbonyl-d-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine d-tartrate
20070249677 - Treatment of osteoarthritis and dosing regimen for arzoxifene
20070249688 - Glucagon receptor antagonists, preparation and therapeutic uses
20070244065 - Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
20070244095 - Compounds and method for treating dyslipidemia
20070237768 - Fgf-21 fusion proteins
20070237775 - Anti-ghrelin antibodies
20070233001 - Injection apparatus having a needle cassette for delivering a pharmaceutical liquid
September 2007 - Eli Lilly & Company patents
20070224188 - Variant fc regions
20070225267 - 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors
20070225372 - Amides as bace inhibitors
20070219507 - Pharmaceutical cartridge piston with rigid core
20070213331 - Pyrrolidine derivatives useful as base inhibitors
20070208003 - Compounds and methods for treating dyslipidemia
20070208024 - Histamine h3 receptor agents, preparation and therapeutic uses
August 2007 - Eli Lilly & Company patents
20070203108 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
20070197604 - Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses
20070197960 - Multiple septum cartridge for medication dispensing device
20070197976 - Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
20070190046 - Anti-abeta antibody
20070191784 - Medication dispensing apparatus with gear set having drive member accommodating opening
20070185161 - Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
20070178095 - Anti-myostatin antibodies
20070179129 - Opioid receptor antagonists
July 2007 - Eli Lilly & Company patents
20070173452 - Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity
20070173526 - Compounds and methods for treating dyslipidemia
20070167379 - Use of spinosyns for wound healing
20070167636 - Improved process for the asymmetric synthesis of duloxetine
20070161087 - Glp-1 fusion proteins
20070161547 - Modulation of survivin expression
20070161567 - Method of reducing the risk of bone fracture
20070155722 - Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
20070155754 - Histamine h3 receptor antagonists, preparation and therapeutic uses
20070155793 - 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
June 2007 - Eli Lilly & Company patents
20070149810 - Vitamin d receptor modulators
20070141052 - Fc region variants
20070142278 - Muteins of fibroblast growth factor 21
20070142293 - Methods of treating diseases with activated protein c
20070142441 - Ampa receptor potentiators
20070142789 - Medication dispensing apparatus configured for rotate to prime and pull/push to inject functionality
20070135484 - Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
20070135485 - Novel mch receptor antagonists
May 2007 - Eli Lilly & Company patents
20070123453 - Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
20070111988 - Selective estrogen receptor modulators
20070112036 - Opioid receptor antagonists
20070112045 - Triazole ppar modulators
20070105759 - Melanocortin receptor 4 (mc4) agonists and their uses
20070105845 - Quinolone derivatives
20070105852 - Thiophene and furan compounds
20070105951 - Phenyl-furan compounds as vitamin d receptor modulators
20070105960 - Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
20070106081 - Bicyclic derivatives as ppar modulators
20070106082 - Substituted benzopyrans as selective estrogen receptor-beta agonists
20070106095 - Vitamin d receptor modulators
20070099909 - N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
20070100133 - Erythropoietic compounds
April 2007 - Eli Lilly & Company patents
20070093526 - 4-amino-piperidine derivatives as monoamine uptake inhibitors
20070088016 - Tricyclic steroid hormone nuclear receptor modulators
20070088018 - Cb1 antagonist compounds
20070088288 - Fixed dose medication dispensing device
20070082907 - Peroxisome proliferator activated receptor modulators
20070083046 - Morpholine derivatives as norepinephrine reuptake inhibitors
20070078166 - Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3] triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
20070078169 - Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
February 2007 - Eli Lilly & Company patents
20070041986 - Synthetic polysaccharide antigens for immunological intervention in disease
20070042022 - Liquid formulations of ractopamine
20070043040 - Inhibitors of akt (protein kinase b)
20070043220 - Pyrazole derivative as ppar modulator
20070036761 - Lentiviral apoe2 gene therapy
20070036806 - Glp-1 analog fusion proteins
20070037788 - Tricyclic steroid hormone nuclear receptor modulators
20070037796 - 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
20070037812 - Phenoxyether derivatives as ppar modulators
20070032554 - Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
20070027185 - Antithrombotic aromatic ethers
January 2007 - Eli Lilly & Company patents
20070021343 - Stabilized teriparatide solutions
20070021344 - Stabilized teriparatide solutions
20070015786 - Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
20070010558 - Opioid receptor antagonists
December 2006 - Eli Lilly & Company patents
20060293223 - Uses of melanocortin-3 receptor (mc3r) agonist peptides
20060293385 - Vitamin d receptor modulators
20060287536 - Phenyl-thiophene type vitamin d receptor modulators
20060281787 - Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
20060276522 - Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
20060276532 - Ampa receptor potentiators
November 2006 - Eli Lilly & Company patents
20060269549 - Tnf-alpha binding molecules
20060269550 - Anti-ghrelin fab antibodies
20060270656 - Substituted piperazines of azepines, oxazepines and thiazepines
20060270713 - 3-aminopyrrolidines as inhibitors of monoamine uptake
20060263345 - Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
20060263849 - Glucagon-like peptide-1 analogs
20060264418 - 6-(2,2,2-trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist
20060257973 - Pseudomycin production by pseudomonas syringae
20060257987 - Ppar modulators
20060258654 - Pyridinylmorpholine derivatives
20060251652 - Cd20 binding molecules
20060252693 - Glucagon-like peptide-1 analogs
20060252916 - Modified glucagon-like peptide-1 analogs
October 2006 - Eli Lilly & Company patents
20060241157 - Heterocyclic ppar modulators
20060241188 - Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
20060233788 - Anti-ghrelin antibodies
20060235222 - Indole-derivative modulators of steroid hormone nuclear receptors
20060228366 - Tumor specific monoclonal antibodies
20060223871 - Thiophene-and thiazolesulfonamides as antineoplastic agents
September 2006 - Eli Lilly & Company patents
20060217290 - Insulin analogs having protracted time action
20060217339 - Antisense oligonucleotide modulation of stat3 expression
20060217351 - Method for treating cardiovascular diseases
20060217372 - Diaryl ethers as opioid receptor antagonist
20060217433 - Sulfonamide derivatives as ppar modulators
20060211734 - (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
20060204489 - Protein c derivatives
20060205041 - Recombinant bovine thrombin
20060205715 - 6-substituted nicotinamide derivatives as opioid receptor antagonists
20060205744 - Fused heterocyclic derivatives as ppar modulators
20060206057 - Medication dispensing apparatus with triple screw threads for mechanical advantage
20060199858 - Substituted benzopyrans as selective estrogen receptor-beta agonists
August 2006 - Eli Lilly & Company patents
20060183736 - Selective estrogen receptor modulators containing a phenylsulfonyl group
20060178438 - Muscarinic agonists
20060173035 - 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
July 2006 - Eli Lilly & Company patents
20060166987 - Opioid receptor antagonists
20060167046 - Histamine h3 receptor antagonists, preparation and therapeutic uses
20060167051 - Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
20060167268 - Growth hormone secretagogues
20060160740 - Use of glp-1 or analogs in treatment of stroke
20060160794 - Tachykinin receptor antagonists
20060153838 - Fc region variants
20060154922 - Muscarinic agonists
20060147945 - Novel secreted proteins and their uses
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Eli Lilly & Company in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Eli Lilly & Company with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|
REGISTER now for FREE 
